Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
5.750
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
148,842
Open
5.750
Bid (Size)
5.780 (2)
Ask (Size)
5.820 (5)
Prev. Close
5.750
Today's Range
5.750 - 5.750
52wk Range
5.620 - 15.74
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
November 20, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
November 15, 2024
Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Performance
YTD
-41.74%
-41.74%
1 Month
-13.01%
-13.01%
3 Month
-21.77%
-21.77%
6 Month
-36.32%
-36.32%
1 Year
-15.19%
-15.19%
More News
Read More
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
November 15, 2024
Via
Investor's Business Daily
Recursion and Exscientia Shareholders Approve the Proposed Combination
November 13, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
November 07, 2024
Via
Benzinga
Peering Into Recursion Pharmaceuticals's Recent Short Interest
November 04, 2024
Via
Benzinga
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
November 12, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
November 11, 2024
Via
Benzinga
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
October 30, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Is Recursion Pharmaceuticals Stock a Buy?
September 20, 2024
Via
The Motley Fool
Looking Into Recursion Pharmaceuticals's Recent Short Interest
September 16, 2024
Via
Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
November 04, 2024
Via
Benzinga
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
November 02, 2024
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
October 26, 2024
Via
The Motley Fool
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
October 22, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 2 Stocks Could Soar in 2025
October 17, 2024
Via
The Motley Fool
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
October 15, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
October 15, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
October 08, 2024
Via
The Motley Fool
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
October 02, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
September 29, 2024
Via
The Motley Fool
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
September 15, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
